Ide196 (Darovasertib) In Combination With Crizotinib Versus Investigator’S Choice Of Treatment As First-Line Therapy In Hla-A2 Negative Metastatic Uveal Melanoma
Posted Date: Apr 25, 2024
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology
- Type of Study: Drug
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
Criteria:
Null
Keywords:
Uveal Melanoma, Metastatic
For More Information:
Ilaina Monroe
NULL
cancer@uchealth.com